Bluejay Investor Presentation Deck

Symphony IL-6 Regulatory Timeline ●●● bluejay DIAGNOSTICS Q4 '21 Began initial clinical trials Q2 '22 FDA feedback; including de novo designation Q1 '22 Filed FDA pre-submission Q4 '22 Filed pre-submission supplement with FDA Q3 '22 Completed initial clinical trials Q1 '23 FDA feedback; study expansion required Q4 '22 Expanded trials to support de novo submission H1 24 Planned FDA submission Q2 '23 Modify trial inclusion to obtain more patient data 2025 Planned commercialization H2 ¹24 Planned FDA submission response Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 11

View entire presentation